Envoy Medical (Envoy Medical) Total Payout Yield % : -2.83 (As of May. 24, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Envoy Medical's current Total Payout Yield % is -2.83%.

Envoy Medical Total Payout Yield % Historical Data

The historical data trend for Envoy Medical's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical Total Payout Yield % Chart

Envoy Medical Annual Data

Trend

Dec21

Dec22

Dec23

Total Payout Yield %

-0.31

Envoy Medical Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Yield %	Get a 7-Day Free Trial				-	-	-	-	-8.76

Competitive Comparison of Envoy Medical's Total Payout Yield %

For the Medical Devices subindustry, Envoy Medical's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Envoy Medical's Total Payout Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Envoy Medical's Total Payout Yield % falls into.

Envoy Medical Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Envoy Medical's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0.109	+	0)	/	35.48776
	=	-0.31%

Envoy Medical's annualized Total Payout Yield % for the quarter that ended in Mar. 2024 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	1.683	+	0)	*	4	/	76.832
	=	-8.76%

Envoy Medical Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Envoy Medical Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Envoy Medical's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Envoy Medical (Envoy Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCH) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4875 White Bear Parkway, White Bear Lake, MN, USA, 55110

Website

https://www.envoymedical.com

Envoy Medical Inc is focused on designing, developing, and marketing fully implantable medical devices that improve hearing. The Company's first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue the development of a cochlear implant.